Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021
WHO CNS5 classification has further stressed the importance of molecular signatures in …

Platinum-based antitumor drugs have been used in many types of tumors due to its broad
antitumor spectrum in clinic. Encouraged by the cisplatin's (CDDP) worldwide success in …

Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve
treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current …

Simple Summary Glioblastomas are the most common and aggressive brain tumors in
adults, with a median survival of 15 months. Treatment is surgical removal, followed by …

Background Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor
prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise …

Simple Summary Glioblastoma is the most common malignant brain tumor associated with a
poor prognosis, with a median survival of 14 months. Despite initial treatment with surgery …

This systematic review assesses current molecular targeted therapies for glioblastoma
multiforme (GBM), a challenging condition with limited treatment options. Using PRISMA …

Simple Summary Glioblastoma is the most common malignant primary brain tumor. Despite
technological advancements and modern therapeutic agents used for treatment, the …

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …

Purpose This review compares reirradiation (reRT), systemic therapy and combination
therapy (reRT & systemic therapy) with regards to overall survival (OS), progression-free …